- Disease: Post-COVID-19
- Study type: Randomised Clinical Trial
- Study type descriptors: Interventional
- Study aim: To evaluate the efficacy and safety of Temelimab as a treatment for post COVID-19 syndrome neuropsychiatric symptoms in patients who had severe acute SARS-CoV-2 infection but did not undergo intensive care treatment during the acute period
- Number of participants enrolled: 203
- Study enrolling from to
- Study includes follow-up for 6 months
Study Data
- Adults
- Elderly
- General population
- Outpatient clinic
- SARS-CoV-2
- Post-COVID-19
- Pharmacological intervention
- Temelimab
- Monoclonal antibodies
External Links
Other information
Funders:
- GeNeuro SA
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to